The foundation collaborates with The ALS Association and other affiliates to translate funding into cutting-edge development tools, promote early detection of ALS, and understand disease heterogeneity. They work with GE, who has developed breakthrough technology called "Mapping the Mind" to gain neurological information. The foundation typically invests in healthcare and pharmaceutical startups that are 2-3 years old. They have invested a significant portion of their budget in target identification efforts and funding clinical trials for ALS treatment.